Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland
Laboratory for the Study of Emotion Elicitation and Expression (E3Lab), Department of Psychology, University of Geneva, Geneva, Switzerland.
BMJ Open. 2021 Sep 21;11(9):e053845. doi: 10.1136/bmjopen-2021-053845.
Being physically active is associated with a wide range of health benefits in patients. However, many patients do not engage in the recommended levels of physical activity (PA). To date, interventions promoting PA in patients mainly rely on providing knowledge about the benefits associated with PA to develop their motivation to be active. Yet, these interventions focusing on changing patients' conscious goals have proven to be rather ineffective in changing behaviours. Recent research on automatic factors (eg, automatic approach tendencies) may provide additional targets for interventions. However, the implementation and evaluation of intervention designed to change these automatic bases of PA are rare. Consequently, little is known about whether and how interventions that target automatically activated processes towards PA can be effective in changing PA behaviours. The Improving Physical Activity (IMPACT) trial proposes to fill this knowledge gap by investigating the effect of a cognitive-bias modification intervention aiming to modify the automatic approach towards exercise-related stimuli on PA among patients.
The IMPACT trial is a single-centre, placebo (sham controlled), triple-blinded, phase 3 randomised controlled trial that will recruit 308 patients enrolled in a rehabilitation programme in the Division of General Medical Rehabilitation at the University Hospital of Geneva (Switzerland) and intends to follow up them for up to 1 year after intervention. Immediately after starting a rehabilitation programme, patients will be randomised (1:1 ratio) to receive either the cognitive-bias modification intervention consisting of a 12-session training programme performed over 3 weeks or a control condition (placebo). The cognitive-bias modification intervention aims to improve PA levels through a change in automatic approach tendencies towards PA and sedentary behaviours. The primary outcome is the sum of accelerometer-based time spent in light-intensity, moderate-intensity and vigorous-intensity PA over 1 week after the cognitive-bias modification intervention (in minutes per week). Secondary outcomes are related to changes in (1) automatic approach tendencies and self-reported motivation to be active, (2) physical health and (3) mental health. Sedentary behaviours and self-reported PA will also be examined. The main time point of the analysis will be the week after the end of the intervention. These outcomes will also be assessed during the rehabilitation programme, as well as 1, 3, 6 and 12 months after the intervention for secondary analyses.
The study will be conducted in accordance with the Declaration of Helsinki. This trial was approved by the Ethics Committee of Geneva Canton, Switzerland (reference number: CCER2019-02257). All participants will give an informed consent to participate in the study. Results will be published in relevant scientific journals and be disseminated in international conferences.
The clinical trial was registered at the German clinical trials register (reference number: DRKS00023617); Pre-results.
积极运动与患者的广泛健康益处相关。然而,许多患者没有达到推荐的身体活动(PA)水平。迄今为止,促进患者 PA 的干预措施主要依赖于提供与 PA 相关的益处知识,以培养他们积极活动的动机。然而,这些专注于改变患者有意识目标的干预措施已被证明在改变行为方面效果甚微。最近对自动因素(例如,自动接近倾向)的研究可能为干预措施提供额外的目标。然而,旨在改变这些 PA 的自动基础的干预措施的实施和评估却很少。因此,尚不清楚针对 PA 的自动激活过程的干预措施是否以及如何能够有效改变 PA 行为。改善身体活动(IMPACT)试验通过研究旨在改变与运动相关刺激的自动接近倾向的认知偏差修正干预措施对日内瓦大学医院综合医学康复科(瑞士)康复计划中招募的 308 名患者的 PA 的影响,旨在填补这一知识空白。
IMPACT 试验是一项单中心、安慰剂(假对照)、三盲、3 期随机对照试验,将招募 308 名在瑞士日内瓦大学医院综合医学康复科参加康复计划的患者,并打算在干预后最多随访 1 年。患者在开始康复计划后立即(1:1 比例)随机分配接受认知偏差修正干预(包括在 3 周内进行 12 次培训课程)或对照组(安慰剂)。认知偏差修正干预旨在通过改变对 PA 和久坐行为的自动接近倾向来提高 PA 水平。主要结局是认知偏差修正干预后 1 周内基于加速度计的轻强度、中等强度和剧烈强度 PA 时间总和(每周分钟数)。次要结局与以下方面的变化有关:(1)自动接近倾向和自我报告的活动积极性,(2)身体健康和(3)心理健康。久坐行为和自我报告的 PA 也将进行检查。分析的主要时间点将是干预结束后的第 1 周。这些结果也将在康复计划期间以及干预后 1、3、6 和 12 个月进行评估,以进行二次分析。
该研究将符合《赫尔辛基宣言》的规定。该试验已获得瑞士日内瓦州伦理委员会的批准(参考编号:CCER2019-02257)。所有参与者都将给予参与研究的知情同意。研究结果将发表在相关科学期刊上,并在国际会议上进行传播。
临床试验在德国临床试验注册处(参考号:DRKS00023617)注册;预结果。